Comment
doi: 10.1056/NEJMc2106424.
Pegcetacoplan versus Eculizumab in PNH
Affiliations
- PMID: 34706182
- DOI: 10.1056/NEJMc2106424
Item in Clipboard
Comment
Pegcetacoplan versus Eculizumab in PNH
N Engl J Med.
.
No abstract available
Comment in
-
Pegcetacoplan versus Eculizumab in PNH. Reply.N Engl J Med. 2021 Oct 28;385(18):1725-1726. doi: 10.1056/NEJMc2106424. N Engl J Med. 2021. PMID: 34706185 No abstract available.
Comment on
-
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.N Engl J Med. 2021 Mar 18;384(11):1028-1037. doi: 10.1056/NEJMoa2029073. N Engl J Med. 2021. PMID: 33730455 Clinical Trial.
Similar articles
-
Pegcetacoplan versus Eculizumab in PNH.N Engl J Med. 2021 Oct 28;385(18):1725. doi: 10.1056/NEJMc2106424. N Engl J Med. 2021. PMID: 34706184 No abstract available.
-
Pegcetacoplan versus Eculizumab in PNH.N Engl J Med. 2021 Oct 28;385(18):1724-1725. doi: 10.1056/NEJMc2106424. N Engl J Med. 2021. PMID: 34706183 No abstract available.
-
Pegcetacoplan versus Eculizumab in PNH. Reply.N Engl J Med. 2021 Oct 28;385(18):1725-1726. doi: 10.1056/NEJMc2106424. N Engl J Med. 2021. PMID: 34706185 No abstract available.
-
Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review.Int J Hematol. 2016 Jun;103(6):703-12. doi: 10.1007/s12185-016-1946-x. Epub 2016 Feb 8. Int J Hematol. 2016. PMID: 26857155 Review.
-
C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.Semin Hematol. 2018 Jul;55(3):130-135. doi: 10.1053/j.seminhematol.2018.05.014. Epub 2018 Jun 5. Semin Hematol. 2018. PMID: 30032749 Review.
Cited by
-
Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study.J Blood Med. 2022 Aug 12;13:425-437. doi: 10.2147/JBM.S361863. eCollection 2022. J Blood Med. 2022. PMID: 35983240 Free PMC article.
-
Inhibition of the different complement pathways has varying impacts on the serum bactericidal activity and opsonophagocytosis against Haemophilus influenzae type b.Front Immunol. 2022 Dec 12;13:1020580. doi: 10.3389/fimmu.2022.1020580. eCollection 2022. Front Immunol. 2022. PMID: 36578495 Free PMC article.
-
The oxygen carrier M101 alleviates complement activation, which may be beneficial for donor organ preservation.Front Immunol. 2022 Sep 12;13:1006761. doi: 10.3389/fimmu.2022.1006761. eCollection 2022. Front Immunol. 2022. PMID: 36172347 Free PMC article.
-
In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway.Front Immunol. 2023 Jun 29;14:1180833. doi: 10.3389/fimmu.2023.1180833. eCollection 2023. Front Immunol. 2023. PMID: 37457736 Free PMC article.
-
Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH.J Blood Med. 2023 Mar 29;14:239-245. doi: 10.2147/JBM.S362220. eCollection 2023. J Blood Med. 2023. PMID: 37016661 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
